TLN-499 with venetoclax for advanced solid tumors that returned or stopped responding
Tests TLN-499 with venetoclax in adults with solid tumors that came back.
Plain-language title generated from the registry record
Registry title: TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Key facts
- Where
- Camperdown, Malvern, and Nedlands, AustraliaSee the 3 sites
- Phase
- Phase 1
Where in Australia
- COBL Clinical Trials - Chris O'Brien LifehouseCamperdown, AustraliaNot yet recruiting
- Cabrini Hospital - MalvernMalvern, AustraliaNot yet recruiting
- Linear Clinical ResearchNedlands, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Treeline Biosciences, Inc.
- Trial code
- NCT07713732
- Record updated
- 1 October 2026
- Original description
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.Read full original descriptionShow less
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Inclusion: Adults ≥18 years of age; Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma; Measurable disease per RECIST v1.1 or mRECIST; ECOG performance status 0-1; Adequate hematologic, hepatic, renal, and coagulation function; Life expectancy ≥12 weeks; Signed informed consent.
Exclusion: Major surgery or severe trauma within 4 weeks before first dose; Use of prohibited concomitant medications; Previous conditions that would interfere with study assessments or safety; Significant uncontrolled medical conditions preventing study participation; Active brain metastases.